Oncotarget as a Reliable Electronic Resource for Cancer Research

Oncotarget is a peer-reviewed open access journal that deals with the care of cancer patients. It looks at the pathology of cancer, treatment procedures and therapy targets to give the best possible care to affected patients. The journal also does in-depth reviews on the latest and existing therapies as well as the quality of life and satisfaction from the patients’ point of view. It also generally covers all aspects of oncology. Oncotarget was launched in 2010 and is published by Impact Journals with Mikhail Blagosklonny and Andrei Gudkov as its editors-in-chief. Visit his profile on Google Scholar.

With the increasing use of e-cigarettes, a paper published on Oncotarget from URMC Rochester concerning the damage it causes on the gum tissue is one of the articles that shows how vital Oncotarget can be. The increase in e-cigarette usage posed an oral health concern leading to the research being done to address this issue. Oncotarget being a stakeholder in oral health matters, published this upon reception from URMC and became available for public consumption for the first time. As such, the platform played a major role in providing this crucial information out to the general public on a global scale.

In this paper, findings showed that e-cigarette vapor caused inflammatory responses and DNA damage in human periodontal ligament fibroblasts, gingival epithelium progenitors, pooled cells, and epi-gingival tissues. This confirmed that e-cigarettes do indeed cause gum tissue damage. The detailed nature of this report is one of the examples that clearly demonstrate how resourceful Oncotarget can be.

The information available on the site can be used by a wide range of individuals from oncologists to students who might find the information useful in their work and study, as well as inform the general public. The information is easily accessible, and Oncotarget offers its users an option to download the published paper for portability and frequent access. It is arguably one of the best electronic resources of information as long as the medical and education sectors are concerned. It is also vital in increasing the impact of its authors’ research by reaching a worldwide audience. Oncotarget currently accepts papers of a wide range of areas other than oncology be it cardiology, neurology, pharmacology among many others and get it out there as far as it is possible. Download output styles at Endnote.com

Eric Lefkofsky: Using His Fortune to Fight Cancer

About Eric

Eric Lefkofsky is currently ranked at #1275 in the world’s billionaires’ list by Forbes with a net worth of $1.88 billion. He has amassed a significant percentage of his fortune from technology-based start-ups. Eric Lefkofsky is the honcho at Groupon, 2010’s fastest growing entity, according to Forbes.

He has also worked in numerous prominent firms over his long career.

Moreover, Lefkofsky is an active contributor to the fight against cancer as well as a passionate humanitarian.

Educational background

South Field Lathrup High was where Eric received his secondary education. He attained his undergraduate BA degree from the University of Michigan. Eric later went to the Law school of the same university, where he was awarded Juris Doctor in 1993 click here.

Accelerated Disruption

The book is an editorial masterpiece written by Eric. The primary subject matter covered is the bringing of entrepreneurial ideas into fruition. This piece is a step-by-step guide for successful businesses. Right from the first page, the book explains how to overcome obstacles as well as how you can transform your business into a client magnet. Additionally, it enlightens employers on how to treat their workers for best output.

Tempus Inc.

Over the years, Eric has displayed unrivaled commitment in the fight against cancer. Not only has he poured a significant amount of dollars towards the cause, but he also inaugurated Tempus Inc., an enterprise whose sole objective is to eradicate this menace.

Tempus is transforming the approach taken in diagnosing cancer. Rather than following conventional methods, the firm uses genetics to establish the extent of the disease. Genetic samples from patients are run through high-end laboratory infrastructure after which personalized medication is given to every client. The company uses modernized lab equipment to enhance the credibility of the test results.

Philanthropy

Eric has been involved in humanitarian causes since 2006 when he started his family foundation. The organization’s objective is to alleviate living standards of the impoverished. Over the years, the charity has supported numerous causes across the country, particularly the terminally ill, with a bias towards cancer patients, contact him.

Additionally, the group runs a mentorship program, named Moneythink. This incentive seeks to educate the youth on various financial issues.

Clay Siegall & The Future of Cancer Fighting Biotechnology

When it comes to illnesses in today’s society, Cancer is one of the worlds most prevalent diseases. These deadly cells can manifest and grow throughout the years in the human in areas such as lungs, pancreas, liver, throat, etc. There have been many treatments for cancer, but none of them has really made a large enough dent to in saving lives. As of 2016, cancer treatment is far more advanced and precise. Antibody Based Therapies are some of the most successful treatments for fighting the illness and destroying the dangerous cells on contact. One of the leading Biotech Companies in the world is Seattle Genetics and this company is changing the current status quo.

Seattle Genetics stands out from the competitors thanks to it’s advanced cancer fighting capabilities, scientific innovation, development, and commercialization of medications. Seattle Genetics has one of the best leaders in the industry as well and it’s his guidance that has pushed the organization to the apex of the field. Clay Siegall is his name and eradicating cancer is his game. This doctor/scientist has knowledge, know-how, expertise, and skill to get the job done and he has a long resume of success to back up all claims. The George Washington University and University of Maryland Graduate has extensive education as Siegall holds a Ph.D in Genetics and a (BS) in Zoology. On top of that, the good doctor holds at least 15 patents of his own and is the author of more than 70 publications. Clay Siegall’s leadership and experience in the game is what help makes him so valuable.

The company’s flagship medicine (ADCETRIS) is one of the most successful at fighting cancerous cells within the body. With this success, the medicines are now available in over 60 countries worldwide. As of the year 2016, Seattle Genetics’ net worth is estimated at $4.7 Billion and Dr. Clay Siegall is in firm control as he continues to steer the ship to future success.When it comes to illnesses in today’s society, Cancer is one of the worlds most prevalent diseases. These deadly cells can manifest and grow throughout the years in the human in areas such as lungs, pancreas, liver, throat, etc. There have been many treatments for cancer, but none of them has really made a large enough dent to in saving lives. As of 2016, cancer treatment is far more advanced and precise. Antibody Based Therapies are some of the most successful treatments for fighting the illness and destroying the dangerous cells on contact. One of the leading Biotech Companies in the world is Seattle Genetics and this company is changing the current status quo.

The company’s flagship medicine (ADCETRIS) is one of the most successful at fighting cancerous cells within the body. With this success, the medicines are now available in over 60 countries worldwide. As of the year 2016, Seattle Genetics’ net worth is estimated at $4.7 Billion and Dr. Clay Siegall is in firm control as he continues to steer the ship to future success.